Cited by 2,514Global Cancer Incidence and ScreeningBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology Studies

The DOI matches its Crossref record; 52 of the 55 references it cites were found in a registry or an index.

Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

Antoni, Sebastien, Ferlay, Jacques, Soerjomataram, Isabelle, Znaor, Ariana, Jemal, Ahmedin, Bray, Freddie·2017·European Urology

DOI 10.1016/j.eururo.2016.06.010

Open this paper in CoChat — free account

Abstract

Context Bladder cancer has become a common cancer globally, with an estimated 430 000 new cases diagnosed in 2012. Objective We examine the most recent global bladder cancer incidence and mortality patterns and trends, the current understanding of the aetiology of the disease, and specific issues that may influence the registration and reporting of bladder cancer. Evidence acquisition Global bladder cancer incidence and mortality statistics are based on data from the International Agency for Research on Cancer and the World Health Organisation (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organisation Mortality). Evidence synthesis Bladder cancer ranks as the ninth most frequently-diagnosed cancer worldwide, with the highest incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. Incidence rates are consistently lower in women than men, although sex differences varied greatly between countries. Diverging incidence trends were also observed by sex in many countries, with stabilising or declining rates in men but some increasing trends seen for women. Bladder cancer ranks 13th in terms of deaths ranks, with mortality rates decreasing particularly in the most developed countries; the exceptions are countries undergoing rapid economic transition, including in Central and South America, some central, southern, and eastern European countries, and the Baltic countries. Conclusions The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking, although infection with Schistosoma haematobium and other risk factors are major causes in selected populations. Differences in coding and registration practices need to be considered when comparing bladder cancer statistics geographically or over time. Patient summary The main risk factor for bladder cancer is tobacco smoking. The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking.

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2016.06.010

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Self-citation
Cancer Incidence in Five Continents
Doll, R., Muir, C. S., & Waterhouse, J. A. H. (1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,485
The United Nations Development Programme
Oestreich, J. E. (2017) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780190637347.003.0003 · Cited by 4,875
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Babjuk, M. M., Andreas Böhle, E., Burger, M., Čapoun, O., Cohen, D. L., Compérat, É., Hernández, V., KAASINEN, E. S., Palou, J., Morgan Rouprêt, A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.041 · Cited by 2,240
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Burger, M., Catto, J. W. F., Dalbagni, G. M., Grossman, H. B., Herr, H. W., Karakiewicz, P. I., Kassouf, W., Kiemeney, L. A. L. M., Vecchia, C. L., Shariat, S. F., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.07.033 · Cited by 2,212
Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk
Steinmann, P., Keiser, J., Bos, R., Tanner, M., & Utzinger, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70521-7 · Cited by 2,146
Smoking prevalence and cigarette consumption in 187 countries, 1980-2012
Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer-Lindgren, L., Thomson, B., Wollum, A., Sanman, E., Wulf, S., Lopez, A. D., et al. (2014) · JAMA · doi:10.1001/jama.2013.284692 · Cited by 1,576
Estimating average annual per cent change in trend analysis
Clegg, L. X., Hankey, B. F., Tiwari, R. C., Feuer, E. J., & Edwards, B. K. (2009) · Statistics in Medicine · doi:10.1002/sim.3733 · Cited by 1,271
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., Sylvester, R. J., Kaasinen, E., Böhle, A., Palou Redorta, J., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.003 · Cited by 1,174

Show all 55 references

Research works printed but not linked: 1

Loader C. Smoothing: Local Regression Techniques Web site. http://hdl.handle.net/10419/22186.

Sorted by citations

Items 801–900 of 1,000

Crosstalk between long non-coding RNA DLX6-AS1, microRNAs and signaling pathways: A pivotal molecular mechanism in human cancers
Alizadeh, A., Jebelli, A., Baradaran, B., Amini, M. A., Oroojalian, F., Hashemzaei, M., Mokhtarzadeh, A., & Hamblin, M. R. (2020) · Gene · doi:10.1016/j.gene.2020.145224 · Cited by 18
Dasatinib induces apoptosis and autophagy by suppressing the PI3K/Akt/mTOR pathway in bladder cancer cells
Ho, J., Byun, S., Kim, D. H., Ryu, H., & Lee, S. (2024) · Korean journal of urology · doi:10.4111/icu.20240250 · Cited by 17
P3H4 is correlated with clinicopathological features and prognosis in bladder cancer
Li, W., Ye, L., Chen, Y., & Chen, P. (2018) · World Journal of Surgical Oncology · doi:10.1186/s12957-018-1507-2 · Cited by 17
Targeted Therapies in Urothelial Bladder Cancer: a Disappointing Past Preceding a Bright Future?
Hindy, J.-R., Souaid, T., Kourié, H. R., & Kattan, J. G. (2019) · Future Oncology · doi:10.2217/fon-2018-0459 · Cited by 17
Identifying Potential Prognostic Markers for Muscle-Invasive Bladder Urothelial Carcinoma by Weighted Gene Co-Expression Network Analysis
Feng, Y., Jiang, Y., Wen, T., Meng, F., & Shu, X. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00657-6 · Cited by 17
Occupational disparities in bladder cancer survival: A population‐based cancer registry study in Japan
Zaitsu, M., Lee, H., Lee, S.-C., Takeuchi, T., Kobayashi, Y., & Kawachi, I. I. (2019) · Cancer Medicine · doi:10.1002/cam4.2768 · Cited by 17
Rapid, Low-Cost Dielectrophoretic Diagnosis of Bladder Cancer in a Clinical Setting
Hoque, R., Mostafid, H. A., & Hughes, M. P. (2020) · IEEE Journal of Translational Engineering in Health and Medicine · doi:10.1109/jtehm.2020.3004743 · Cited by 17
LncRNA DANCR regulates lymphatic metastasis of bladder cancer via the miR-335/VEGF-C axis
Ping, Q., Shi, Y., Yang, M., Li, H., Zhong, Y., Li, J., Bi, X., & Wang, C. (2021) · Translational Andrology and Urology · doi:10.21037/tau-21-226 · Cited by 17
Silencing circ‑BIRC6 inhibits the proliferation, invasion, migration and epithelial‑mesenchymal transition of bladder cancer cells by targeting the miR‑495‑3p/XBP1 signaling axis
Zhou, L., Wang, B., Zhang, Y., Yao, K., & Liu, B. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12451 · Cited by 17
miR-616-5p Promotes Invasion and Migration of Bladder Cancer via Downregulating NR2C2 Expression
Ren, W., Hu, J., Li, H., Chen, J., Ding, J., Zu, X., & Fan, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.762946 · Cited by 17
Immune Checkpoint and Telomerase Crosstalk Is Mediated by miRNA-138 in Bladder Cancer
Ahanidi, H. E., Azzouzi, M. E., Alaoui, C. H., Tetou, M., Bensaid, M., Chaoui, I., Benbacer, L., Hassan, I., Oukabli, M., Michaud, K., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.795242 · Cited by 17
MiR-7-5p suppresses invasion via downregulation of the autophagy-related gene ATG7 and increases chemoresistance to cisplatin in BCa
Wang, C., Tang, Z., Zhang, Z., Liu, T., Zhang, J., Huang, H., & Li, Y. (2022) · Bioengineered · doi:10.1080/21655979.2022.2037323 · Cited by 17
Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer
Sun, X., Xin, S., Jin, L., Zhang, Y., & Ye, L. (2022) · Bioengineered · doi:10.1080/21655979.2022.2085284 · Cited by 17
Epigenetic regulation of MIR145 core promoter controls miR-143/145 cluster in bladder cancer progression and treatment outcome
Pilala, K., Papadimitriou, M., Panoutsopoulou, K., Barbarigos, P., Levis, P. K., Kotronopoulos, G., STRAVODIMOS, K. G., Scorilas, A., & Avgeris, M. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.10.001 · Cited by 17
A Comparative Study of Deep Neural Networks for Real-Time Semantic Segmentation during the Transurethral Resection of Bladder Tumors
Varnyú, D., & Szirmay‐Kalos, L. (2022) · Diagnostics · doi:10.3390/diagnostics12112849 · Cited by 17
Fibronectin 1 as a Key Gene in the Genesis and Progression of Cadmium-Related Bladder Cancer
Zhang, L., Wang, Y., Song, M., Chang, A., Zhuo, W., & Zhu, Y. (2022) · Biological Trace Element Research · doi:10.1007/s12011-022-03510-1 · Cited by 17
Prognostic nomogram based on the lymph node metastasis indicators for patients with bladder cancer: A SEER population‐based study and external validation
Li, S., Wang, Y., & Hu, X. (2022) · Cancer Medicine · doi:10.1002/cam4.5475 · Cited by 17
Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer
Seok, J., Kwak, H. J., Kwak, Y., Lee, M., Park, K. S., Kim, A., & Cho, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03972-4 · Cited by 17
CircHIPK3 negatively regulates autophagy by blocking VCP binding to the Beclin 1 complex in bladder cancer
Wang, C., Liu, T., Wang, J., Cheng, C., Zhang, Z., Zhang, J., Huang, H., & Li, Y. (2023) · Discover Oncology · doi:10.1007/s12672-023-00689-0 · Cited by 17
Increased expression of long non-coding RNA CCEPR is associated with poor prognosis and promotes tumorigenesis in urothelial bladder carcinoma
Zhan, Y., Li, Y., Guan, B., Chen, X., Chen, Z., He, A., He, S., Gong, Y., Ding, P., Liu, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17872 · Cited by 17
Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer
Álvarez-Arguedas, S., Uranga, S., Martín, M. D. M., Elizalde, J., Gómez, A. B., Julián, E., Nardelli‐Haefliger, D., Martı́n, C., & Aguiló, N. (2018) · Translational research · doi:10.1016/j.trsl.2018.03.004 · Cited by 19
Glutathione S-Transferase Pi 1 (GSTP1) Gene 313 A/G (rs1695) polymorphism is associated with the risk of urinary bladder cancer: Evidence from a systematic review and meta-analysis based on 34 case-control studies
Song, Y., Chen, J., Liu, K., Zhou, K., Lü, Y., Wang, X., Yang, Y., & Liu, X. (2019) · Gene · doi:10.1016/j.gene.2019.144077 · Cited by 18
Propofol exhibits a tumor‑suppressive effect and regulates cell viability, migration and invasion in bladder carcinoma by targeting the microRNA‑10b/HOXD10 signaling pathway
Qi, Z., Yuan, L., & Sun, N. (2019) · Oncology Letters · doi:10.3892/ol.2019.10968 · Cited by 17
Retracted
Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers
Jeeta, R. R., Gordon, N. S., Baxter, L. A., Goel, A., Noyvert, B., Ott, S., Boucher, R. H., Humayun-Zakaria, N., Arnold, R. R., James, N. D., et al. (2019) · Bladder Cancer · doi:10.3233/blc-190251 · Cited by 17
Oncogenic roles of the cholesterol metabolite 25‑hydroxycholesterol in bladder cancer
Wang, C., He, H., & Fang, W. (2020) · Oncology Letters · doi:10.3892/ol.2020.11475 · Cited by 17
Evaluation of ASPM and TEF Gene Expressions as Potential Biomarkers for Bladder Cancer
Saleh, A. A., Gohar, S. F., Hemida, A. S., Elgharbawy, M., & Soliman, S. E.-S. (2020) · Biochemical Genetics · doi:10.1007/s10528-020-09962-1 · Cited by 17
Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma
Wang, Y., Chen, L., Ju, L., Xiao, Y., & Wang, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106818 · Cited by 17
Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression
Lobo, J., Monteiro‐Reis, S., Guimarães‐Teixeira, C., Lopes, P., Carneiro, I. C., Jerónimo, C., & Henrique, R. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02475-w · Cited by 17
Pharmaceutical Evaluation of Honokiol and Magnolol on Apoptosis and Migration Inhibition in Human Bladder Cancer Cells
Wang, H.-H., Chen, Y., Changchien, C., Chang, H., Lu, P.-J., Mariadas, H., Cheng, Y., & Wu, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.549338 · Cited by 17
Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker
Elsawy, A. A., Awadalla, A., Abdullateef, M., Ahmed, A. E., & Abol‐Enein, H. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.02.009 · Cited by 17
Microfluidic Assaying of Circulating Tumor Cells and Its Application in Risk Stratification of Urothelial Bladder Cancer
Fu, G., Cheng, K. S., Chen, A., Xu, Z., Chen, X., Tian, J., Xu, C., Sun, Y., Neoh, K. H., Dai, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701298 · Cited by 17
YKL-40 promotes invasion and metastasis of bladder cancer by regulating epithelial mesenchymal transition
Hao, H., Chen, H., Xie, L., & Liu, H. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1950920 · Cited by 17
High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer
Sikic, D., Eckstein, M., Weyerer, V., Kubon, J., Breyer, J., Roghmann, F., Kunath, F., Keck, B., Erben, P., Hartmann, A., et al. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.06.021 · Cited by 17
Urine TERT promoter mutations‑based tumor DNA detection in patients with bladder cancer: A pilot study
Jain, M., Kamalov, D. M., Tivtikyan, A. S., Balatsky, A., Samokhodskaya, L. M., Okhobotov, D. A., Kozlova, P., Pisarev, E., Zvereva, M. I., & Kamalov, A. A. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2415 · Cited by 18
Correlation between High PD-L1 and EMT/Invasive Genes Expression and Reduced Recurrence-Free Survival in Blood-Circulating Tumor Cells from Patients with Non-Muscle-Invasive Bladder Cancer
Morelli, M. B., Amantini, C., Vermandois, J. A. R. D., Gubbiotti, M., Giannantoni, A., Mearini, E. E., Maggi, F., Nabissi, M., Marinelli, O., Santoni, M., et al. (2021) · Cancers · doi:10.3390/cancers13235989 · Cited by 17
Regional policy in the EU : a passing phase of Europeanisation or a complex case of policy transfer?
Wishlade, F. G., Yuill, D., & Méndez, C. (2004) · Cited by 17
Gemcitabine-Resistant Biomarkers in Bladder Cancer are Associated with Tumor-Immune Microenvironment
Song, Y., Du, Y., Qin, C., Liang, H., Yang, W., Lin, J., Ding, M., Han, J., & Xu, T. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.809620 · Cited by 17
Impact of Circadian Rhythms on the Development and Clinical Management of Genitourinary Cancers
Kaur, P., Mohamed, N., Archer, M., Figueiro, M. G., & Kyprianou, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.759153 · Cited by 17
Circular RNA SMARCA5 is overexpressed and promotes cell proliferation, migration as well as invasion while inhibits cell apoptosis in bladder cancer
Tan, Y., Zhang, T., & Liang, C. Y. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.08.08 · Cited by 17
Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
Moreo, E., Uranga, S., Picó, A., Gómez, A. B., Nardelli‐Haefliger, D., del Fresno, C., Murillo, I., Puentes, E., Rodríguez, E., Valés‐Gómez, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004325 · Cited by 17
LncRNA SNHG3 enhances BMI1 mRNA stability by binding and regulating c‐MYC : Implications for the carcinogenic role of SNHG3 in bladder cancer
Xie, J., Ni, J., Shi, H., Wang, K., Ma, X., Li, W., & Peng, B. (2022) · Cancer Medicine · doi:10.1002/cam4.5316 · Cited by 17
CRISPR-ON-Mediated KLF4 overexpression inhibits the proliferation, migration and invasion of urothelial bladder cancer in vitro and in vivo
Xu, X., Li, J., Zhu, Y., Xie, B., Wang, X., Wang, S., Xie, H., Yan, H., Ying, Y., Lin, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22158 · Cited by 17
Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
Srivastava, T., Prabhu, V. S., Li, H., Xu, R., Zarabi, N., Zhong, Y., Pellissier, J. M., Perini, R. F., de Wit, R., & Mamtani, R. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.09.012 · Cited by 17
Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy
Nielsen, N. K., Lam, G. W., Fabrin, K., Holt, P. S., Thind, P. O., & Jensen, J. B. (2019) · Scandinavian Journal of Urology · doi:10.1080/21681805.2019.1624608 · Cited by 17
Early Online Attention Can Predict Citation Counts for Urological Publications: The #UroSoMe_Score
Sathianathen, N. J., Lane, R., Condon, B., Murphy, D. G., Lawrentschuk, N., Weight, C., & Lamb, A. D. G. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.10.015 · Cited by 17
Piezo1/ ITGB1 Synergizes With Ca 2+ / YAP Signaling to Propel Bladder Carcinoma Progression via a Stiffness‐Dependent Positive Feedback Loop
Ma, M., Li, J., Li, X., Jing, M., Wang, L., Jiang, Y., Yang, Z., He, J., Wang, M., Liu, H., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71059 · Cited by 20
Hyperthermic Agent Prepared by One-Pot Modification of Maghemite Using an Aliphatic Polyester Model
Segura, T., Pereira, E. D., Icart, L. P., Fernandes, E. R., Oliveira, G. E., & de Souza, F. G. (2018) · Polymer Science Series B · doi:10.1134/s1560090418060106 · Cited by 16
Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.
Francolini, G., Desideri, I., Detti, B., Cataldo, V. D., Masi, L., Caramia, G., Visani, L., Terziani, F., Muntoni, C., Russo, M. L., et al. (2019) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2019.100124 · Cited by 17
Self‐Assembled Nanoparticle‐Mediated Chemophototherapy Reverses the Drug Resistance of Bladder Cancers through Dual AKT/ERK Inhibition
Yu, W., Xue, X., Ma, A., Ruan, Y., Zhang, H., Fan, C., Li, Y., Pan, C.-X., & Lin, T. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000032 · Cited by 16
The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer
Gordetsky, J., Montgomery, K. W., Giannico, G. A., Rais‐Bahrami, S., Thapa, P. B., Boorjian, S. A., Frank, I., Craig, J., & Cheville, J. C. (2021) · International Journal of Surgical Pathology · doi:10.1177/10668969211027264 · Cited by 16
MiR-599 targeting TOP2A inhibits the malignancy of bladder cancer cells
Zhang, F., & Wu, H. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.06.069 · Cited by 16
Andrographolide Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer Cells by Interfering with NF- κ B and PI3K/AKT Signaling In Vitro and In Vivo
Xuan, L., Hu, J., Bi, R., Liu, S.-Q., & Wang, C. (2022) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-022-3464-4 · Cited by 16
Prognosis Risk Model Based on Pyroptosis-Related lncRNAs for Bladder Cancer
Lu, Z., Tang, F., Li, Z., Lai, Y., Lu, Z., Zhang, J., Tang, Z., Cai, W., & He, Z. (2022) · Disease Markers · doi:10.1155/2022/7931393 · Cited by 16
Utility of urinary biomarkers in primary haematuria: Systematic review and meta‐analysis
Soputro, N. A., Gracias, D. N., Dias, B. H., Nzenza, T. C., O’Connell, H. E., & Sethi, K. D. (2022) · BJUI Compass · doi:10.1002/bco2.147 · Cited by 16
Prognostic significance and identification of basement membrane-associated lncRNA in bladder cancer
Feng, L., Yang, J., Zhang, W., Wang, X., Li, L., Peng, M., & Luo, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.994703 · Cited by 16
Chronic conditions and depressive symptoms in middle-aged and older Chinese adults: Roles of perceived social support and area of residence
Miao, Y.-F., Dong, X., Li, D., Zhang, T., Wu, Y., & Pan, C. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.08.045 · Cited by 16
Twenty-two-year incidence trend of urological cancers in the Republic of Korea: 1999–2020
Cho, S., & Park, W.-J. (2023) · Korean journal of urology · doi:10.4111/icu.20230247 · Cited by 16
Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment
Ma, J., Hu, J., Zhao, L., Wu, Z., Li, R., & Deng, W. (2024) · BMC Urology · doi:10.1186/s12894-023-01354-y · Cited by 16
Prediction of non-muscle invasive bladder cancer recurrence using deep learning of pathology image
Wang, G.-Y., Zhu, J., Wang, Q., Qin, J., Wang, X., Liu, X., Liu, X., Chen, J., Zhu, J., Zhuo, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-66870-9 · Cited by 16
Systemic therapy in bladder cancer
Pinto, I. G. (2017) · Indian Journal of Urology · doi:10.4103/iju.iju_294_16 · Cited by 16
Reversine induces autophagic cell death through the AMP-activated protein kinase pathway in urothelial carcinoma cells
Fang, C., Chen, J.-S., Chang, S.-K., & Shen, C. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000563 · Cited by 16
Sonic Hedgehog Expression is Associated with Lymph Node Invasion in Urothelial Bladder Cancer
Nedjadi, T., Salem, N., Khayyat, D., Al-Sayyad, A., Al-Ammari, A., & Al-Maghrabi, J. A. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0477-6 · Cited by 16
Reduction of Muscle-Invasive Tumors by Photodynamic Therapy with Tetrahydroporphyrin-Tetratosylat in an Orthotopic Rat Bladder Cancer Model
Berndt‐Paetz, M., Schulze, P., Stenglein, P. C., Weimann, A., Wang, Q., Horn, L., Riyad, Y. M., Griebel, J., Hermann, R., Glasow, A., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1194 · Cited by 16
Coffee and tea drinking and risk of cancer of the urinary tract in male smokers
Hashemian, M., Sinha, R. R., Murphy, G. A., Weinstein, S. J., Liao, L. M., Freedman, N. D., Abnet, C. C., Albanes, D., & Loftfield, E. (2019) · Annals of Epidemiology · doi:10.1016/j.annepidem.2019.03.014 · Cited by 16
Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers
Guillamón, C. F., Gimeno, L., Server, G., Martínez‐Sánchez, M. V., Escudero, J. F., López-Cubillana, P., Cabezas‐Herrera, J., Campillo, J. A., Abellán, D., Martínez-García, J., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.04.009 · Cited by 16
En bloc resection of bladder tumors: indications, techniques, and future directions
Territo, A., Bevilacqua, G., Meneghetti, I., Mercadé, A., & Breda, A. (2020) · Current Opinion in Urology · doi:10.1097/mou.0000000000000737 · Cited by 16
Bladder neoplasms and NF-κB: an unfathomed association
Walter, C. E. J., Durairajan, S., Kalaiselvi, P., Doss, C. G. P., Dicky John Davis, G., Vasanthi, H. R., Johnson, T., & Zayed, H. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1743688 · Cited by 16
Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer
Balakrishnan, A., Washington, S. L., Meng, M. V., & Porten, S. P. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.01.007 · Cited by 16
Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
Kim, H., Lee, S. J., Lee, I. K., Min, S. C., Sung, H. H., Jeong, B. C., Lee, J., & Park, S. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082825 · Cited by 16
Trends and Utilization of Inpatient Palliative Care Among Patients With Metastatic Bladder Cancer
Han, H., Yu, F., Wu, C., Dai, L., Ruan, Y., Cao, Y., & He, J. (2020) · Journal of Palliative Care · doi:10.1177/0825859720924936 · Cited by 16
16-Hydroxycleroda-3,13-Dien-15,16-Olide Induces Apoptosis in Human Bladder Cancer Cells through Cell Cycle Arrest, Mitochondria ROS Overproduction, and Inactivation of EGFR-Related Signalling Pathways
Chen, Y., Wang, P.-Y., Huang, B.-M., Chen, Y.-J., Lee, W.-C., & Chen, Y.-J. (2020) · Molecules · doi:10.3390/molecules25173958 · Cited by 16
Cell blocks in urine cytopathology: do they add value to the diagnosis? A pilot study
Wilson, B. L., Russell, D. K., Evans, S., & Agrawal, T. (2020) · Journal of the American Society of Cytopathology · doi:10.1016/j.jasc.2020.08.003 · Cited by 16
LINC00649 promotes bladder cancer malignant progression by regulating the miR‑15a‑5p/HMGA1 axis
Chen, X., & Chen, S. (2021) · Oncology Reports · doi:10.3892/or.2021.7959 · Cited by 16
MicroRNA‑16‑5p/BIMP1/NF‑κB axis regulates autophagy to exert a tumor‑suppressive effect on bladder cancer
He, J., Qiu, Z., Zhang, H., Gao, Z., Jiang, Y., Li, Z., Kong, C., & Man, X. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12215 · Cited by 16
Copy number variation analysis of m6A regulators identified METTL3 as a prognostic and immune‐related biomarker in bladder cancer
Wang, X., Yu, J., Chen, J., Hou, Y., Du, Z., Huang, H., Tang, S., Han, Y., Ding, C., & Xue, Z. (2021) · Cancer Medicine · doi:10.1002/cam4.3981 · Cited by 16
ZNF652-Induced circRHOT1 Promotes SMAD5 Expression to Modulate Tumorigenic Properties and Nature Killer Cell-Mediated Toxicity in Bladder Cancer via Targeting miR-3666
Hu, K., Zhang, J., Wang, F., & Xiong, Y. (2021) · Journal of Immunology Research · doi:10.1155/2021/7608178 · Cited by 16
miR-148a-3p inhibits the proliferation and migration of bladder cancer via regulating the expression of ROCK-1
Xu, C., Zhou, G., Sun, Z., Zhang, Z., Zhao, H., & Jiang, X. (2022) · PeerJ · doi:10.7717/peerj.12724 · Cited by 16
KLF16 Downregulates the Expression of Tumor Suppressor Gene TGFBR3 to Promote Bladder Cancer Proliferation and Migration
Chen, X., Wang, P., Ou, T., & Li, J. (2022) · Cancer Management and Research · doi:10.2147/cmar.s334521 · Cited by 16
Benchmarking PASADENA Consensus along the Learning Curve of Robotic Radical Cystectomy with Intracorporeal Neobladder: CUSUM Based Assessment
Lombardo, R., Mastroianni, R., Tuderti, G., Ferriero, M. C., Brassetti, A., Anceschi, U., Guaglianone, S., Nunzio, C. D., Cicione, A. M., Tubaro, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245969 · Cited by 16
CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients
Castellano, E., Samba, C., Esteso, G., Simpson, L. J., Vendrame, E., García‐Cuesta, E. M., López‐Cobo, S., Álvarez‐Maestro, M., Linares, A., Leibar, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.970931 · Cited by 16
Identification of a dysregulated CircRNA-associated gene signature for predicting prognosis, immune landscape, and drug candidates in bladder cancer
Shen, C., Li, Z., Zhang, Y., Zhang, Z., Wu, Z., Da, L., Yang, S., Wang, Z., Zhang, Y., Qie, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1018285 · Cited by 16
Ligustilide induces apoptosis and reduces proliferation in human bladder cancer cells by NFκB1 and mitochondria pathway
Yin, L., Lu, Y., Guo, R., Hao, M., Liang, Y., Bi, Y., Chen, Y., Yu, C., & Yang, Z. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14207 · Cited by 17
Ubenimex, an APN inhibitor, could serve as an anti‑tumor drug in RT112 and 5637 cells by operating in an Akt‑associated manner
Wang, X., Yang, L., Liu, W., Zhang, Y., Guo, F., Zhang, L., Cui, M., Liu, S., & Wu, R. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8402 · Cited by 16
Diagnostic accuracy of the UBC� Rapid Test for bladder cancer: A meta‑analysis
Lü, P., Cui, J., Chen, K., Lü, Q., Zhang, J., Tao, J., Han, Z., Zhang, W., Song, R., & Gu, M. (2018) · Oncology Letters · doi:10.3892/ol.2018.9089 · Cited by 16
Health related quality of life after urinary diversion. Which technique is better?
Moeen, A. M., Safwat, A. S., Gadelmoula, M. M., Moeen, S. M., Abonnoor, A. E. I., Abbas, W., ElGanainy, E. O., & El-Taher, A. M. (2018) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2018.08.001 · Cited by 16
Norcantharidin inhibits the DDR of bladder cancer stem-like cells through cdc6 degradation
Shi, X., Chen, S., Zhang, Y., Xie, W., Hu, Z., Li, H., Li, J., Zhou, Z., & Tan, W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s209907 · Cited by 16
A Pilot Study of Radiotherapy and Local Hyperthermia in Elderly Patients With Muscle-Invasive Bladder Cancers Unfit for Definitive Surgery or Chemoradiotherapy
Datta, N. R., Stutz, E., Puric, E., Eberle, B., Meister, A., Marder, D., Timm, O., Rogers, S. J., Wyler, S. F., & Bodis, S. B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00889 · Cited by 16
How does hypervirulent Klebsiella pneumoniae influence the risk and visual outcomes of endogenous endophthalmitis in Klebsiella pneumoniae pyogenic liver abscess? A systematic review and meta analysis
Chen, K.-Y., Chan, H.-C., & Chan, C.-M. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.103090 · Cited by 15
Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer
Amestoy, F., Roubaud, G., Antoine, M., Fonteyne, V., Baumann, B. C., Christodouleas, J. P., Morgan Rouprêt, A., Azria, D., Zilli, T., Hennequin, C., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.06.010 · Cited by 15
Knockdown of lncRNA ZNRD1‐AS1 inhibits progression of bladder cancer by regulating miR‐194 and ZEB1
Gao, Z., Li, S., Xufeng, Z., Li, H., & He, S. (2020) · Cancer Medicine · doi:10.1002/cam4.3373 · Cited by 15
Identification of metabolism-associated genes and construction of a prognostic signature in bladder cancer
Shen, C., Liu, J., Wang, L., Liang, Z., Niu, H., & Wang, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01627-8 · Cited by 15
Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis
Huang, H., Yan, B., Hao, H., Shang, M., He, Q., Liu, L., & Xi, Z. (2021) · International Journal of Urology · doi:10.1111/iju.14537 · Cited by 15
A Novel Ferroptosis-Related Gene Model for Overall Survival Predictions of Bladder Urothelial Carcinoma Patients
Zhang, M., Zhang, X., Yu, M., Zhang, W., Zhang, D., Zeng, S., Wang, X., & Hu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698856 · Cited by 15
Risk of malignancy in kidney transplant recipients: a nationwide population-based cohort study
Jung, S. W., Lee, H., & Cha, J. M. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02796-6 · Cited by 15
CNN1 Represses Bladder Cancer Progression and Metabolic Reprogramming by Modulating HIF-1α Signaling Pathway
Zhang, Z., Li, X., ren, S., & Zhang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.859707 · Cited by 16
A global, regional, and national survey on burden and Quality of Care Index (QCI) of bladder cancer: The global burden of disease study 1990–2019
Karimi, A., Shobeiri, P., Azadnajafabad, S., Masinaei, M., Rezaei, N., Ghanbari, A., Rezaei, N., Rouhifard, M., Shahin, S., Rashidi, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275574 · Cited by 15
Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Han, S. H., & Yuk, H. D. (2023) · Journal of Urologic Oncology · doi:10.22465/juo.234600080004 · Cited by 15
STIL/AURKA axis promotes cell proliferation by influencing primary cilia formation in bladder cancer
Li, J., Qi, Y., Li, B., Liu, Y., Yang, K., Zhang, Z., Zhu, J., & Du, E. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04118-2 · Cited by 15
LC-MS based urine untargeted metabolomic analyses to identify and subdivide urothelial cancer
Yang, M., Liu, X., Tang, X., Sun, W., & Ji, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1160965 · Cited by 15
Cancer in Migrants: A Population-Based Study in Italy
Collatuzzo, G., Ferrante, M., Ippolito, A., Prima, A. A. D., Colarossi, C., Scarpulla, S., Boffetta, P., & Sciacca, S. (2023) · Cancers · doi:10.3390/cancers15123103 · Cited by 16

Authors: Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F.
Affiliations: Centre international de recherche sur le cancer (FR)
American Cancer Society (US)
Corresponding author: Bray, Freddie
ORCID: Ferlay, Jacques
Soerjomataram, Isabelle
Znaor, Ariana
Jemal, Ahmedin
Bray, Freddie
Venue: European Urology
Publisher: Elsevier BV
Published: 2017-01
Volume: 71
Issue: 1
Pages: 96-108
ISSN: 0302-2838 (ISSN-L)
DOI: 10.1016/j.eururo.2016.06.010
OpenAlex: W2473162054
Cited by: 2,514
References: 55
Citations by year: 2026: 79 · 2025: 165 · 2024: 248 · 2023: 244 · 2022: 314 · 2021: 414 · 2020: 400 · 2019: 306 · 2018: 225 · 2017: 102
FWCI: 21.58
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: European Urology (publishedVersion)
PubMed (publishedVersion)
Funders: World Health Organization
Topics: Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
Keywords: bladder cancer, cancer incidence, cancer mortality, incidence trends, sex differences, smoking, Schistosoma haematobium, etiology, global cancer statistics
MeSH terms: Urinary Bladder Neoplasms, Female, Humans, Male, Registries, Risk Factors, Smoking, Global Health, Incidence, Internationality

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks